Ascelia Pharma Acquisitions (Net)
Acquisitions (Net) of Ascelia Pharma (ACE.ST) as of Oct 13, 2026.
Get this data via API
Financial Data API
Acquisitions (Net)
0.00SEK
Last updated:
Acquisitions (Net) of Ascelia Pharma is 2025 0.00 SEK. Acquisitions (Net) of Ascelia Pharma was 2024 0.00 SEK. It decreases by % lower compared to the previous year.
The Ascelia Pharma Acquisitions (Net) history
3 Years
10 Years
25 Years
Max
Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2019
0.00 SEK
Jan 1, 2020
76.39 M SEK
Jan 1, 2021
0.00 SEK
Jan 1, 2023
47,000.00 SEK
Jan 1, 2024
0.00 SEK
Jan 1, 2025
0.00 SEK
| YEAR | Acquisitions (Net) | YoY |
|---|---|---|
| 0.00SEK | — | |
| 0.00SEK | -100.00% | |
| 47,000.00SEK | — | |
| 0.00SEK | -100.00% | |
| 76.39 MSEK | — | |
| 0.00SEK | — |
Access this data via the Eulerpool API
Ascelia Pharma Stock analysis
What does Ascelia Pharma do? Ascelia Pharma is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Ascelia Pharma stock
On Eulerpool you can find the complete historical development of Acquisitions (Net) Ascelia Pharma since 2006 – with annual values, charts, and detailed analysis.
Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.
Acquisitions (Net)'s SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s Ascelia Pharma historically and in real time.
Access this data via the Eulerpool API
Cash Flow — Ascelia Pharma
Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A
All Key Metrics — Ascelia Pharma
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth